2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

antibody-conjugated drug

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

2

Inhibitory Antibodies

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145767A
    SN-38-CO-DMEDA TFA

    		Drug Intermediate Others
    SN-38-CO-DMEDA TFA is the intermediate product for synthesizing antibody-conjugated drug LND1035 .
    SN-38-CO-DMEDA TFA
  • HY-13631F
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan, as a drug-linker conjugate composed of linker Gly-Gly-Phe-Gly-NH-O-CO and Exatecan, can be used to prepare antibody conjugate drugs. Exatecan is a DNA topoisomerase I inhibitor that can be used in cancer research .
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride
  • HY-19792
    Mertansine
    15+ Cited Publications

    DM1; Maytansinoid DM1

    		 Microtubule/Tubulin ADC Cytotoxin Cancer
    Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .
    Mertansine
  • HY-P99016B
    Enfortumab vedotin-ejfv (solution)

    		Antibody-Drug Conjugates (ADCs) Nectin-4 Cancer
    Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable maleimidocaproylvaline-citrulline linker (SGD-1006). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
    Enfortumab vedotin-ejfv (solution)
  • HY-P99016A
    Enfortumab vedotin-ejfv

    		Antibody-Drug Conjugates (ADCs) Nectin-4 Cancer
    Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable maleimidocaproylvaline-citrulline linker (SGD-1006). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
    Enfortumab vedotin-ejfv
  • HY-153360
    MC-GGFG-AM-(10Me-11F-Camptothecin)

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .
    MC-GGFG-AM-(10Me-11F-Camptothecin)
  • HY-163487
    Puxitatug samrotecan drug-linker

    AZD8205 drug-linker

    		 Drug-Linker Conjugates for ADC Cancer
    Puxitatug samrotecan drug-linker (AZD8205 drug-linker) is part of the anti-B7-H4 antibody-conjugated active molecule ADC (drug-linker conjugate for ADC). Puxitatug samrotecan drug-linker contains a degradable ADC linker and a topoisomerase I inhibitor Exatecan (HY-13631) .
    Puxitatug samrotecan drug-linker
  • HY-141606
    Anetumab ravtansine

    BAY 94-9343

    		 Microtubule/Tubulin Antibody-Drug Conjugates (ADCs) Cancer
    Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .
    Anetumab ravtansine
  • HY-19792S1
    Mertansine-d9

    DM1-d9; Maytansinoid DM1-d9

    		 Isotope-Labeled Compounds Microtubule/Tubulin ADC Cytotoxin Cancer
    Mertansine-d9 (DM1-d9) is deuterium labeled Mertansine. Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .
    Mertansine-d9

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: